Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation.

Xuesen LiVictor PhamMatthew TippinDongjun FuRaymond RendonLiankun SongEdward UchioBang H HoangXiaolin Zi

Published in: Cell communication and signaling : CCS (2019)

These findings provide a rationale for further investigating combination of FKB and Bortezomib for treatment of RB deficient, castration-resistant prostate cancer.

Keyphrases

prostate cancer
multiple myeloma
newly diagnosed
clinical trial
protein protein
small molecule
wild type